Non-Cleaving Single-Nucleotide and Epitranscriptome Editing

23 concepts17 papers1 proposal

Traditional CRISPR-Cas9 tools operate like molecular scissors: they cut both strands of the DNA double helix, creating a double-strand break (DSB). The cell then scrambles to repair this damage using error-prone pathways like non-homologous end joining (NHEJ). While this is highly effective for disrupting genes via random insertions or deletions (indels), it is fundamentally ill-suited for precision engineering. Forcing a DSB to achieve a single-nucleotide correction introduces severe risks, including large-scale deletions, translocations, and chromosomal instability.

To achieve true surgical precision, a paradigm shift was required: decoupling targeting from cleaving. Instead of cutting the molecular backbone, modern precision editing platforms treat CRISPR proteins as programmable, RNA-guided scaffolds. By inactivating or impairing the cleavage domains of these proteins, researchers can use them as spatial anchors to deliver chemical-modifying enzymes directly to a specific coordinate on a DNA or RNA strand.

The Mechanics of DNA Base Editing

The core intuition behind DNA base editing relies on the structural behavior of a Cas protein when it binds its target. When a guide RNA finds its matching sequence, the Cas protein unzips the DNA double helix, creating a localized, single-stranded "bubble."

By fusing a catalytically impaired Cas9 (such as a nickase or a dead Cas9) to a deaminase enzyme, this single-stranded bubble becomes a highly specific chemical reaction window. As reviewed by Shuiquan Li et al. in their work on Harnessing the evolving CRISPR/Cas9 for precision oncology, this architecture allows for the direct conversion of one nucleotide into another without fracturing the DNA backbone. This strategy prioritizes binding flexibility and spatial positioning over raw cleavage speed, a concept termed non-cleavage genomic modulation by Lin Zhao et al. in their development of PAM-flexible chimeric variants like SpRYc (PAM-flexible genome editing with an engineered chimeric Cas9).

Traditional CRISPR-Cas9:
Target DNA  =======[ CUT ]=======  --> Double-Strand Break --> Messy Repair (Indels)

Base Editing Scaffold:
Target DNA  ===( Single-Stranded Bubble )===
                     |
               [ dCas9/nCas9 ]--[ Deaminase Enzyme ] --> Direct Chemical Conversion (C->T or A->G)

As detailed by Lukas Villiger et al. in CRISPR technologies for genome, epigenome and transcriptome editing, standard base editors are chemically categorized by the types of point mutations they induce:

  • Transitions: Swapping a purine for a purine, or a pyrimidine for a pyrimidine. This is the primary domain of Cytosine Base Editors (CBEs, converting C-to-T) and Adenine Base Editors (ABEs, converting A-to-G).
  • Transversions: Swapping a chemical class (e.g., a pyrimidine to a purine, such as C-to-G), which requires specialized, next-generation transversion editors or prime editors.

Because these systems bypass DSBs, they offer unprecedented safety and efficiency in complex biological environments. For instance, Meiling Zhang et al. demonstrated that mRNA-encoded base editors could achieve robust, clean homozygotic nucleotide substitutions in human embryos (Human cleaving embryos enable robust homozygotic nucleotide substitutions by base editors).

In large-animal modeling, where multiplexed editing with standard Cas9 typically triggers catastrophic chromosomal rearrangements, base editing shines. Lin Yang et al. successfully deployed CBEs and ABEs to simultaneously knock out multiple porcine antigens for xenotransplantation without inducing genomic instability (Advance of genetically modified pigs in xeno-transplantation). Similarly, Jiangping Song et al. utilized the CBE4max/BE3 system to precisely introduce premature stop codons into the PKP2 gene of pigs, creating a highly faithful large-animal model of Arrhythmogenic Cardiomyopathy without unwanted collateral mutations (PKP2杂合敲除诱导的致心律失常性心肌病猪模型与表型分析).

This clean, predictable mechanism has even expanded beyond agriculture (W. Z. Tan et al.) into digital technology. Jiaojiao Jiang highlights how nucleotide base editing can be leveraged for DNA digital data storage, where writing data via direct chemical conversion drastically minimizes the biochemical noise and error rates associated with traditional nuclease-driven writing methods (Application of gene editing technology to DNA digital data storage).

Moving to the Transcriptome: Programmable RNA Base Editing

The scaffold philosophy is not restricted to the genome. The discovery of Cas13 (originally designated C2c2) by Omar Abudayyeh et al. introduced a single-component, programmable RNA-guided protein that targets single-stranded RNA molecules rather than DNA (C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector).

By rendering Cas13 catalytically inactive (dCas13), researchers can harness its targeting precision to manipulate transcripts transiently. As reviewed by Guanglin Zhu et al. in CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics, fusing dCas13 to ADAR (adenosine deaminase acting on RNA) or cytidine deaminases allows for precise A-to-I (read as G) or C-to-U editing directly on mRNA.

A prominent example is the RESCUE system, evaluated by Guo Li et al., which pairs an inactive Cas13b ortholog with an engineered cytidine deaminase to drive targeted C-to-U conversions (Transcription-wide impact by RESCUE-induced off-target single-nucleotide variants in mammalian cells). Because RNA is naturally transient and turned over by the cell, this approach offers a completely reversible way to repair pathogenic mutations or alter cellular signaling pathways without risking permanent, off-target alterations to the host genome (J Engreitz et al.).

Surgical Control of the Epitranscriptome

Beyond changing the primary sequence of RNA bases, cells regulate their biology through an intricate layer of chemical decorations on RNA transcripts—the epitranscriptome. The most abundant and influential of these modifications is $N^6$-methyladenosine ($m^6A$), which dictates mRNA stability, localization, and translation efficiency.

To understand or manipulate these pathways, researchers have extended the non-cleaving CRISPR scaffold concept to epitranscriptomic engineering. As outlined by Lisha Shen et al. in Recent advances in the plant epitranscriptome, fusing dead RNA-targeting proteins to epitranscriptomic "writers" (methyltransferases) or "erasers" (demethylases) enables site-specific control over the chemical state of individual transcripts.

Epitranscriptome Editing:
Target mRNA  =======( Specific Adenosine )=======
                            |
                      [ dCas13 ]--[ Methyltransferase / Demethylase ] 
                                            |
                                  Adds or removes m6A mark 
                                  (Alters translation/stability)

This approach allows scientists to establish direct causality between a single chemical mark and a macroscopic disease phenotype. For example, Yongbo Pan et al. utilized a CRISPR-Cas13 system fused with an $m^6A$ demethylase to selectively strip methylation marks from the CDC25A transcript (m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle). They demonstrated that removing this single mark destabilized the mRNA, halting the cell cycle and suppressing tumor growth in esophagogastric junction adenocarcinoma.

Furthermore, as noted by Mingliang Yi et al., this capacity to write and erase $m^6A$ marks at will provides a powerful lever for modulating complex cellular machinery, such as telomerase activity, offering a non-genetic, highly tunable strategy for therapeutics in oncology and regenerative medicine (CRISPR-based m6A modification and its potential applications in telomerase regulation).

Key Foundational Work

CRISPR Tools for Systematic Studies of RNA Regulation (2019) — contributed 1 concept elements to this direction.
Human cleaving embryos enable robust homozygotic nucleotide substitutions by base editors (2019) — contributed 1 concept elements to this direction.
C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector (2016) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_single_nucleotide_base_editing_3eee6603,
  title = {single-nucleotide base editing},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/single-nucleotide-base-editing/rdr_3eee66032f0c4fc88f4ba33245e0fdd4},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_single_nucleotide_base_editing_3eee6603_v1,
  title = {single-nucleotide base editing},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/single-nucleotide-base-editing/rdr_3eee66032f0c4fc88f4ba33245e0fdd4/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake